<DOC>
	<DOCNO>NCT00555048</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab , find cancer cell either kill deliver cancer-killing substance without harm normal cell . Giving chemotherapy drug , busulfan cyclophosphamide , donor stem cell transplant help stop growth cancer cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving tacrolimus methotrexate transplant may stop happen . PURPOSE : This phase I/II trial study best dose alemtuzumab give together busulfan cyclophosphamide follow donor stem cell transplant see well work treat patient hematologic cancer .</brief_summary>
	<brief_title>Alemtuzumab , Busulfan , Cyclophosphamide Followed By Donor Stem Cell Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Identify low dose alemtuzumab associate day 180 transplant-related mortality ≤ 45 % . Secondary - Determine incidence life-threatening infection patient receive treatment . - Determine incidence grade III-IV acute graft-vs-host disease ( GVHD ) patient receive treatment . - Determine survival 1 year patient receive treatment . - Determine incidence disease relapse 1 year patient receive treatment . - Determine incidence extensive chronic GVHD 1 year patient receive treatment . - Determine incidence graft failure day 100 patient receive treatment . OUTLINE : - Chemotherapy : Patients receive alemtuzumab IV 2 hour day -10 -6 , busulfan IV 3 hour day -7 -4 , cyclophosphamide IV day -3 -2 . - Peripheral blood stem cell ( PBSC ) transplantation : Patients undergo allogeneic filgrastim ( G-CSF ) -mobilized PBSC transplantation day 0 . - Graft-vs-host disease prophylaxis : Patients receive tacrolimus IV continuously orally twice daily day -1 50 methotrexate IV day 1 , 3 , 6 , 11 . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis one following : Primary acute myeloid leukemia ( AML ) meeting follow criterion : First complete remission ( CR ; define &lt; 5 % blast marrow ) highrisk feature define failure achieve remission day 21 induction chemotherapy , presence chromosomal abnormality involve following : 5/del ( 5q ) 7/del ( 7q ) Inversion 3q Abnormalities 11q23 , 20q , 21q , del ( 9q ) , Translocation 6 ; 9 Translocation 9 ; 22 Abnormalities 17p Complex karyotype ≥ 3 abnormality Second CR subsequent remission Refractory relapse disease Secondary AML remission relapse Chronic myelogenous leukemia ( CML ) accelerate blast phase meeting follow criterion : Accelerated phase define one following : Blasts 10 % 19 % peripheral blood white cell bone marrow cell Peripheral blood basophil ≥ 20 % Persistent thrombocytopenia ( &lt; 100,000/mm³ ) unrelated therapy , persistent thrombocytosis ( &gt; 1,000,000/mm³ ) unresponsive therapy Increasing spleen size increase WBC count unresponsive therapy Cytogenetic evidence clonal evolution ( i.e. , appearance additional genetic abnormality present initial specimen time diagnosis chronic phase CML ) Blast phase define follow : Blasts ≥ 20 % peripheral blood white cell bone marrow cell Extramedullary blast proliferation Large focus cluster blast bone marrow biopsy Primary myelodysplastic syndrome ( MDS ) IPSS score &gt; 1.5 Secondary MDS IPSS score Primary acute lymphoblastic leukemia meeting follow criterion : First CR ( &lt; 5 % blast marrow ) highrisk feature define 1 following : Failure achieve remission first induction chemotherapy Presence chromosomal abnormality include hypodiploidy abnormality 11q23 translocation 9 ; 22 Second CR subsequent remission Refractory relapse disease No patient suitable HLA genotypically identical sibling fully match HLAA , B , C , DRB1 unrelated donor available No active CNS involvement disease Donors must meet following criterion : Unrelated volunteer donor mismatch one HLAclass I alleles antigens one HLAclass I antigen , match highresolution type HLADRB1 DQB1 , OR mismatch one HLAclass II alleles antigen , match highresolution type HLAA , B , C No twoantigen mismatch single HLAA , B , C locus No mismatch class I class II HLA Matching must base result highresolution type HLAA , B , C , DRB1 , DQB1 PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % No symptomatic coronary artery disease symptomatic congestive heart failure No hepatic disease transaminases bilirubin &gt; 2 time upper limit normal except isolated hyperbilirubinemia attribute Gilbert 's syndrome No severe hypoxemia room air P_AO_2 &lt; 70 , supplemental oxygendependence , DLCO &lt; 60 % predict No impaired renal function creatinine &gt; 2 time upper limit normal creatinine clearance &lt; 50 % normal Not HIV seropositive Not pregnant breastfeed Fertile patient must use effective contraception No active infection untreated fail respond appropriate therapy PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Exclusion criterion : Prior allogeneic autologous bone marrow , peripheral blood stem cell , umbilical cord blood transplantation use highdose totalbody irradiation regimen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>